Plaque Reduction Neutralization Test

The Plaque Reduction Neutralization Test (PRNT) is the reference quantitative virological and serological bioassay used to measure the concentration (titer) of functional virus-neutralizing antibodies (nAbs) in human or animal serum, plasma, cerebrospinal fluid, or monoclonal antibody preparations. Adapted from Renato Dulbecco's 1952 invention of the animal-virus plaque assay on confluent vertebrate cell monolayers (Dulbecco, 1952; Russell et al., 1967), the PRNT incubates serial dilutions of heat-inactivated test serum with a standardized challenge dose of live, replication-competent infectious virus (typically 50 to 100 Plaque-Forming Units [PFU]) before inoculating the mixture onto a permissive cell monolayer overlaid with a semi-solid matrix (agarose, methylcellulose, or carboxymethylcellulose). Whereas solid-phase binding assays (ELISA, immunofluorescence, or lateral-flow immunoassays) detect all antibodies that bind viral proteins regardless of biological activity, PRNT quantifies the subset of antibodies capable of blocking viral attachment, receptor engagement, endocytosis, or conformational endosomal membrane fusion—serving as the World Health Organization (WHO) and U.S. Food and Drug Administration (FDA) regulatory gold standard for differentiating cross-reactive flaviviruses (dengue virus, Zika virus, West Nile virus, and yellow fever virus) and establishing correlates of protection in clinical vaccine trials.

When a vertebrate host is infected by a virus or immunized with a viral antigen, the humoral B-cell response generates a polyclonal mixture of immunoglobulins (IgM, IgG1–IgG4, IgA) directed against both surface-exposed conformational epitopes and internal structural epitopes:

• Non-Neutralizing Binding Antibodies (bAbs): Bind denatured, internal (such as orthoflavivirus NS1 or nucleocapsid C), or cryptic surface epitopes (such as the conserved fusion loop [FL, residues 98–110] of Domain II on the orthoflavivirus Envelope [E] dimer) without preventing the virion from entering host cells. In standard IgM/IgG ELISA or hemagglutination-inhibition (HAI) assays, these non-neutralizing antibodies generate false-positive cross-reactive signals across the Orthoflavivirus genus (up to 50–80% amino acid identity across E proteins) and can promote Fcγ-receptor-mediated uptake into myeloid cells at sub-neutralizing concentrations (antibody-dependent enhancement [ADE]).
• Functional Neutralizing Antibodies (nAbs): Bind quaternary or domain-specific epitopes on the native virion surface (such as the Domain III [EDIII] lateral ridge or E-dimer epitope [EDE] bridging two adjacent E monomers on dengue and Zika virions) with sufficient occupancy (the "multiple-hit" stoichiometric model, requiring ~30 to 120 bound IgG molecules per 180-E-monomer flavivirus particle) to block cellular receptor attachment or cross-link the surface glycoprotein lattice so that it cannot undergo the low-pH-triggered dimer-to-trimer conformational rearrangement required for endosomal membrane fusion.

Because PRNT measures the survival and plaque-forming capacity of live infectious virions after antibody engagement, only antibodies that functionally abort the viral entry/fusion cycle reduce the plaque count.

Standardized PRNT protocols (WHO, 2007) proceed through five controlled experimental stages:

1. Serum Heat-Inactivation and Serial Dilution

Test sera, alongside reference antisera (WHO International Standards), negative controls, and back-titration controls, are heat-inactivated in a 56 °C water bath for 30 minutes. This step destroys heat-labile serum complement proteins (C1q, C3, C4) and adventitious viral inhibitors, ensuring that neutralization reflects intrinsic antibody affinity and stoichiometry rather than variable complement-mediated virolysis. Heat-inactivated sera are diluted in buffered cell-culture medium (MEM or DMEM with 2% fetal bovine serum) in two-fold (1:10, 1:20, 1:40, ..., 1:2,560) or four-fold (1:10, 1:40, 1:160, 1:640, 1:2,560, 1:10,240) serial dilutions.

2. Virus–Serum Neutralization Incubation

An equal volume (100–250 μL) of each serum dilution is mixed 1:1 with a pre-titrated stock of live reference virus adjusted to deliver 50 to 100 Plaque-Forming Units (PFU) per well (yielding 30–80 countable non-overlapping plaques in a 6-well or 12-well plate). A parallel Virus Dose Control (Back-Titration: 100%, 50%, 10%, and 1% of the challenge virus input) verifies that the infectious input lies within 30–100 PFU/well. The mixtures are incubated for 60 minutes at 37 °C (in 5% CO₂) or 16–18 hours at 4 °C to reach binding equilibrium.

3. Permissive Cell Monolayer Inoculation and Adsorption

Growth medium is aspirated from confluent monolayers of permissive indicator cells—typically African green monkey kidney (Vero or Vero E6), rhesus monkey kidney (LLC-MK2), or baby hamster kidney (BHK-21) cells—in 6-, 12-, or 24-well plates. Replicate wells are inoculated with each neutralized virus–serum mixture and rocked every 15 minutes for 60 minutes at 37 °C to allow surviving un-neutralized virions to adsorb and internalize.

4. Semi-Solid Overlay Application (Restricting Cell-Free Diffusion)

After adsorption, the monolayer is overlaid with maintenance medium containing a viscous or gelling polymer: 0.8–1.0% low-melting-point agarose / Noble agar or 0.8–1.5% carboxymethylcellulose (CMC) / methylcellulose (MC). The semi-solid overlay prevents progeny virions released from an initially infected cell from diffusing freely by convection through the liquid supernatant. Instead, progeny virions spread only laterally to contiguous neighbor cells. Over 3 to 7 days at 37 °C, each single surviving infectious virion produces one circular zone of lysed cells (1–4 mm diameter)—a plaque (1 Plaque = 1 surviving PFU).

5. Fixation, Staining, and Plaque Enumeration

Monolayers are either fixed with 10% buffered formalin / 4% paraformaldehyde and counter-stained with 0.5–1.0% crystal violet (where plaques appear as clear unstained circular holes against a purple cell lawn) or stained vitally with 0.01–0.03% neutral red (taken up into acidic lysosomes of living cells).

Computing Percentage Plaque Reduction and Endpoint Titers

For each serum dilution D, let N_D be the mean plaque count in test wells and N₀ be the mean plaque count in the Virus-Only Control (100% infectivity reference, e.g., 60 PFU):

% Plaque Reduction = [1 − (N_D / N₀)] × 100%

The neutralizing antibody titer is the reciprocal of the highest serum dilution reducing N₀ by a specified threshold, interpolated via four-parameter nonlinear logistic regression (4PL), Probit regression, or Reed–Muench / Kärber analysis:

• PRNT₅₀ (50% Plaque Reduction Endpoint): Lying at the steepest inflection point of the sigmoidal dose–response curve, PRNT₅₀ has the lowest variance and is the regulatory endpoint for vaccine immunogenicity trials (where PRNT₅₀ ≥ 1:10 is the accepted protective threshold for Japanese encephalitis, Yellow Fever, and Measles vaccines [≥ 120 mIU/mL]).
• PRNT₈₀ and PRNT₉₀ (80% and 90% Plaque Reduction Endpoints): Required by the WHO and CDC for diagnostic serology in flavivirus-co-endemic regions (distinguishing Zika virus from secondary dengue virus DENV-1–4 or West Nile virus, where a PRNT₉₀ titer ≥ 4-fold higher against the infecting virus overcomes cross-reactive "original antigenic sin").

While PRNT remains the regulatory benchmark, its 5–7 day turnaround, large well format, manual plaque-counting, and requirement for Biosafety Level 3 (BSL-3) or BSL-4 biocontainment for high-consequence pathogens have driven the adoption of three high-throughput derivatives:

Why is PRNT90 preferred over PRNT50 for diagnosing Zika vs. Dengue infections?

In tropical regions where multiple orthoflaviviruses co-circulate, an individual who previously had dengue (DENV-1–4) or yellow fever vaccination and is later infected with Zika virus mounts an anamnestic ("original antigenic sin") antibody response dominated by cross-reactive antibodies against conserved epitopes on the viral Envelope (E) protein. At the 50% plaque reduction threshold (PRNT₅₀), these cross-reactive antibodies frequently neutralize both Zika and dengue at high titers (making the specific infecting virus ambiguous). Using the more stringent PRNT₉₀ (90% plaque reduction) filters out low-avidity cross-reactive antibodies so that only high-avidity type-specific neutralizing antibodies register, allowing definitive diagnosis when one virus shows a ≥4-fold higher PRNT₉₀ titer than all others.

Why must serum samples be heated to 56 °C for 30 minutes before running a PRNT?

Fresh or frozen unheated serum contains active complement cascade proteins (C1q through C9), which vary widely in concentration depending on how the blood sample was collected, stored, and thawed. Active C1q and C3b bind to antibody-coated virions and either sterically enhance neutralization or lyse enveloped virions via the C5b–9 membrane attack complex, artificially inflating neutralizing titers in a non-reproducible manner. Heating serum to 56 °C for 30 minutes irreversibly denatures heat-labile complement components (specifically C1q, C2, and Factor B) without harming heat-stable IgG and IgM antibodies.

How can sub-neutralizing antibody titers measured below the PRNT50 threshold cause Antibody-Dependent Enhancement (ADE)?

In dengue virus infections, when heterotypic binding antibodies (acquired from a prior infection with a different dengue serotype or via decaying maternal placental transfer) are present at sub-neutralizing concentrations—meaning the number of IgG molecules bound per virion falls below the stoichiometric threshold (~30 molecules) required to block fusion in a PRNT—the antibody-coated virion remains fusion-competent. Instead of neutralizing the virus, the exposed Fc tails of the bound IgG molecules tether the live virion to FcγIIA and FcγIIIA receptors on monocytes, macrophages, and dendritic cells, increasing viral uptake and replication 10- to 1,000-fold (antibody-dependent enhancement).

1. Dulbecco, R. (1952). Production of plaques in monolayer tissue cultures by single particles of an animal virus. Proceedings of the National Academy of Sciences, 38(8), 747–752. https://doi.org/10.1073/pnas.38.8.747
2. Russell, P. K., Nisalak, A., Sukhavachana, P., & Vivona, S. (1967). A plaque reduction test for dengue virus neutralizing antibodies. The Journal of Immunology, 99(2), 285–290. https://doi.org/10.4049/jimmunol.99.2.285
3. Roehrig, J. T., Hombach, J., & Barrett, A. D. T. (2008). Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunology, 21(2), 123–132. https://doi.org/10.1089/vim.2008.0007
4. Pierson, T. C., Xu, Q., Nelson, S., Oliphant, T., Nybakken, G. E., Fremont, D. H., & Diamond, M. S. (2007). The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host & Microbe, 1(2), 135–145. https://doi.org/10.1016/j.chom.2007.03.002